

9. (Amended) The method of claim 7 further comprising contacting the target biomolecule with at least one of said highly ranked members to provide a complex between the [RNA] target biomolecule and the member or members;
- ionizing said complex;
 - fragmenting the ionized complex; and
 - determining whether highly ranked members binds to the molecular interaction site of said biomolecule.

REMARKS

Claims 11-16 have been canceled without prejudice as being directed to non-elected inventions. Claims 6 and 9 have been amended to correct typographical errors. Upon entry of the present amendment, claims 1-10 and 17-20 will be pending.

New pages 1-7 are provided to comply with the Sequence Rules set forth in 37 CFR § 1.821-1.825. In addition, please find enclosed herewith a copy of the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures, a Response to Notice To Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosure, a Statement to Support Filing and Submission of DNA/Amino Acid Sequences in Accordance with 37 CFR §§ 1.821 through 1.825, and a computer readable form (CRF).

The application as filed on May 12, 1998 contained pages 169-170 which contained the Sequence Listing, separate from the specification. A Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures mailed January 13, 2000 indicated that the application failed to comply with rules set forth in 37 CFR 1.821-1.825. The enclosed new pages 1-7 contain the amended Sequence Listing, formatted under the new rules for submitting Sequence Listings, support for which can be found throughout the application as originally filed. The specification has also been amended to incorporate the sequence identification numbers. No new matter has been added. In addition, the contents of the paper copy of the Sequence Listing and computer readable copy of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), are the same.

DOCKET NO.: IBIS-0007

PATENT

Applicants have elected Group I containing claims 1-10 and 17-20 directed to methods of identifying compounds which modulate biomolecule activity in response to the Restriction Requirement mailed October 4, 1999. The Office Action mailed January 13, 2000 requests that Applicants elect a species of biomolecular targets chosen from a) peptides or proteins, b) oligosaccharides, c) nucleic acids, d) glycopeptides, e) antibodies, f) receptors, and g) enzymes. Applicants elect c) nucleic acids. Claims 1-5 and 17-20 already recite RNA. In addition, claims 6-10 include nucleic acids as a target biomolecule.

Applicants submit that the present response is complete and complies with the requirements of 35 U.S.C. § 121.

Respectfully submitted,



Paul K. Legaard

Registration No. **38,534**

Date: **February 3, 2000**

WOODCOCK WASHBURN KURTZ
MACKIEWICZ & NORRIS LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
(215) 568-3100
(215) 568-3439 telefacsimile